secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001493152-25-010977
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma publishes study showing CD105 blockade restores osimertinib sensitivity in NSCLC
--------------------------------------------------------------------------------

- Study in Drug Resistance Updates shows CD105 upregulation drives resistance to EGFR-targeted therapy osimertinib.
- Preclinical models: ENV105 (carotuximab) combined with osimertinib restored drug sensitivity via metabolic reprogramming.
- CEO states CD105 is a central resistance mechanism across prostate, breast, colon, and lung cancers.
- ENV105 currently in Phase 2 for castrate-resistant prostate cancer and Phase 1 for lung cancer.
- Global NSCLC treatment market projected to reach $45B by 2030; drug resistance remains a major challenge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225010977/0001493152-25-010977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225010977/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-010977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer